Placebo to MK-6194 clinical trials

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants with Non-Segmental Vitiligo.

This study is testing a new medicine, MK-6194, for adults with a type of vitiligo called non-segmental vitiligo. Researchers want to see if the medicine can help reduce white patches on the face and if it's safe to use, compared to a dummy medicine.